Drug intelligence / Profile preview

KT051

Development stage: Preclinical
Lead developer: Nanjing Kati Medical Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KT051 is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting Claudin 18.2 (CLDN18.2), currently in preclinical development by Nanjing Kati Medical Technology. CLDN18.2 is a tight junction protein that is highly expressed in several solid tumors, including gastric and pancreatic cancers, while showing limited expression in normal tissues. By engineering T cells to express a CAR specific for CLDN18.2, KT051 aims to selectively target and eliminate malignant cells, providing a potential therapeutic option for patients with CLDN18.2-positive gastrointestinal malignancies.

Other names: KT051KT-051KT 051

Beyond the preview

Go deeper on KT051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT051.

Explore the full profile